Survey Supports Blood Tests for Colorectal Cancer Screening

A growing number of Americans may be ready for a shift in how colorectal cancer screening is delivered, according to a Guardant Health, Inc. news release from

Results from a new national survey, approximately 92% of adults eligible for screening believe blood-based colorectal cancer tests should be widely accessible and covered by insurance, similar to Medicare.

The findings, based on a survey conducted by The Harris Poll on behalf of Guardant Health, highlight both strong public support for newer screening options and ongoing challenges with traditional methods. For patients, these results underscore an important issue: although screening can detect colorectal cancer early, many individuals still delay or avoid testing altogether.

The survey also points to a potential solution. Blood-based screening tests, which require only a simple blood draw, may help increase participation by offering a more convenient and less invasive alternative.

Blood-based screening could improve colorectal cancer detection

The survey results reveal strong enthusiasm for blood-based screening options among adults aged 45 and older, the group recommended for routine colorectal cancer screening. Approximately 92% of respondents said these tests should be covered with no out-of-pocket costs, similar to existing Medicare coverage policies.

Beyond coverage, the data suggest that access to blood-based tests could significantly influence patient behavior. Approximately 77% of respondents reported they would be less likely to delay or avoid screening if a blood test were available.

This is particularly important because screening adherence remains a major barrier in colorectal cancer prevention. Even though screening can detect cancer at earlier, more treatable stages, many individuals do not complete recommended tests.

The survey also found that 85% of respondents would be more likely to follow up with a colonoscopy if they first received a positive result from a blood-based test.

These findings suggest that blood tests may not replace traditional screening methods but could serve as an important first step, encouraging more patients to enter the screening process.

Barriers to traditional screening remain significant

Colorectal cancer remains one of the leading causes of cancer-related death in the United States. Early detection is critical, with survival rates improving significantly when the disease is diagnosed at an early stage.

Despite this, millions of eligible individuals remain unscreened. The survey highlights several reasons why patients may avoid traditional screening methods such as colonoscopy or stool-based tests.

Approximately 71% of respondents reported feeling anxious about undergoing a colonoscopy. More than half, approximately 54%, said stool-based tests are unappealing or uncomfortable to complete. Additionally, approximately 38% indicated they may have difficulty completing stool-based testing altogether.

These barriers contribute to delays in screening, which can result in later-stage diagnoses and fewer treatment options.

Blood-based tests aim to address these concerns by simplifying the screening process. Because they can be completed during a routine health care visit, they may help reduce both logistical and emotional barriers.

Survey methods and patient population

The survey was conducted between February 24 and February 26, 2026, and included 1,189 adults in the United States aged 45 and older.

This age group reflects current screening guidelines, which recommend that individuals at average risk for colorectal cancer begin screening at age 45.

Participants were asked about their attitudes toward colorectal cancer screening, including preferences for different testing methods, perceived barriers and views on insurance coverage.

The results were weighted to reflect the broader U.S. population.

By focusing on screening-eligible adults, the survey provides insight into real-world challenges and opportunities to improve adherence to recommended screening practices.

Additional findings highlight role of blood tests in screening

The survey findings also align with emerging clinical data on blood-based colorectal cancer screening tests, such as Shield, an FDA-approved option for average-risk adults aged 45 and older.

In real-world use, this test has demonstrated approximately 93% adherence among the first 100,000 patients who were offered the option, suggesting that convenience plays a key role in whether individuals complete screening.

Experts note that increasing screening rates is essential to reducing colorectal cancer mortality. Blood-based tests may help close the gap by reaching individuals who might otherwise remain unscreened.

At the same time, these tests are intended to complement, not replace, existing screening methods. A positive result typically requires follow-up with a colonoscopy to confirm findings and guide next steps.

Looking ahead, broader insurance coverage and inclusion in clinical guidelines may further expand access to these tests. For patients, this could mean more options to choose from when deciding how to approach screening.

Ultimately, the survey highlights a clear message: improving access to convenient, patient-friendly screening tools may play a critical role in detecting colorectal cancer earlier and improving outcomes.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

References

1. “New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare,” by Guardant Health, Inc. News release; March 13, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.